Clinical trials: Dapagliflozin
Alzheimer Disease
Dapagliflozin In Alzheimer's Disease
This is a pilot randomized controlled trial in individuals with probable Alzheimer's disease testing the effects of 10 mg dapagliflozin, taken daily for 12 weeks, on cerebral n-acetyl aspartate (NAA) levels using magnetic…
- Trial name
- NCT03801642
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Jeff Burns, MD
Type 2 Diabetes
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
This is a single center, prospective, randomized, placebo -controlled, parallel design and double blind study to evaluate oxidative stress, inflammation and hypertension markers and mediators before and after treatment with…
- Trial name
- NCT02433678
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University at Buffalo
Chronic Heart Failure With Reduced Systolic Function
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart…
- Trial name
- DEFINE-HF (NCT02653482)
- Testing
- Dapagliflozin
- Where
- 25 sites in United States
- Volunteers
- 263 people
- Sponsor
- Saint Luke's Health System
Type 2 Diabetes
A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
The purpose of this clinical research study is to learn if BMS-512148, added to insulin and one or two anti-diabetes medications (metformin and/or pioglitazone or rosiglitazone), can help reduce the blood sugar levels compared to…
- Trial name
- NCT00357370
- Testing
- Dapagliflozin
- Where
- 23 sites in United States, Canada
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Pancreas Cancer, Pancreatic Cancer
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
- Trial name
- NCT04542291
- Testing
- Dapagliflozin, BIOSENSE meters
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Type 1 Diabetes Mellitus
The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM
This randomized, single-blind, 3 arm, parallel group, placebo controlled PK/PD study will enrol 30 Japanese male and female patients with T1DM and age 18 to 65 years, with inadequate glycemic control on insulin defined as HbA1c ≥…
- Trial name
- NCT02582840
- Testing
- Dapagliflozin 5mg, Dapagliflozin 10mg
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation
This is a multicenter trial to evaluate the impact of treatment with dapagliflozin versus placebo following catheter ablation of atrial fibrillation (AF) on the burden of AF during 6-12 months of follow-up.
- Trial name
- DAPA-AF (NCT04792190)
- Testing
- dapagliflozin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Rochester
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking…
- Trial name
- NCT00528372
- Testing
- Dapagliflozin, Metformin
- Where
- 78 sites in United States, Canada and 2 more
- Volunteers
- 1,067 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
- Trial name
- NCT01498185
- Testing
- Dapagliflozin
- Where
- 12 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug…
- Trial name
- NCT01646320
- Testing
- Dapagliflozin, Saxagliptin, Metformin immediate release (IR)
- Where
- 66 sites in United States, Czechia and 6 more
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
The purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and (2) oral glucose tolerance…
- Trial name
- DAPA MITO (NCT01439854)
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Chronic Kidney Disease
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria.
- Trial name
- MIRO-CKD (NCT06350123)
- Where
- 92 sites in United States, Austria and 13 more
- Volunteers
- 324 people
- Sponsor
- AstraZeneca
Type2 Diabetes, High Blood Sugar
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who…
- Trial name
- NCT01294436
- Testing
- Dapagliflozin
- Where
- 38 sites in Japan
- Volunteers
- 728 people
- Sponsor
- AstraZeneca
Type2 Diabetes, Cardiovascular Diseases
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
The purpose of this study is to evaluate the effect of dapagliflozin, a FDA approved diabetes medication, on measures of nervous system function of the heart in patients with type 2 diabetes.
- Trial name
- NCT02973477
- Testing
- Dapagliflozin, Glimepiride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Michigan
Aging
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose…
- Trial name
- SGLT2i (NCT04401904)
- Testing
- Dapagliflozin 10 mg, Nutritional counseling
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using…
- Trial name
- ACHIEVE-2 (NCT06192108)
- Testing
- Orforglipron, Dapagliflozin
- Where
- 74 sites in United States, China and 4 more
- Volunteers
- 962 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency
This proposed study will test whether measurement of breath acetone (BrAce) can be used for the purpose of identifying ketosis (elevated ketones) in persons with type 1 diabetes (T1D).
- Trial name
- NCT05541484
- Testing
- SGLT2 inhibitor, Biosense Breath Ketone Analyzer
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Type 2 Diabetes Mellitus, Myocardial Fibrosis
Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2
There is an unmet need for Cardiovascular Disease (CVD) risk reduction in patients with Type 2 Diabetes. In recent trials there has been promising findings of more effective glucose management and reductions in overall CVD events…
- Conditions
- Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
- Trial name
- NCT03782259
- Testing
- dapagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Washington
Heart Failure, Diabetes Mellitus, Type 2
Efficacy and Safety of Dapagliflozin in Acute Heart Failure
This is a randomized trial of the addition of dapagliflozin to patients with or without type 2 diabetes hospitalized with acute decompensated heart failure (ADHF).
- Trial name
- DICTATE-AHF (NCT04298229)
- Testing
- Dapagliflozin 10 MG, Protocolized Diuretic Therapy
- Where
- 6 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vanderbilt University Medical Center